Skip to main content
SpringerLink
Log in

NICE AS recommendation for adalimumab

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Abbott.NICE Recommends Abbott's Adalimumab (HUMIRA(R)) for the Treatment of Severe Active Ankylosing Spondylitis. Media Release: 28 May 2008. Available from: URL: http://www.abbott.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

NICE AS recommendation for adalimumab. Pharmacoecon. Outcomes News 555, 6 (2008). https://doi.org/10.2165/00151234-200805550-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805550-00010

Keywords

Search

Navigation